S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
206. Galalae RM, Martinez A, Nuernberg N, Edmundson G, Gustafson G, Gonzalez J, Kimming B.
Hypofractionated conformal HDR brachytherapy in hormone naive men with localized
prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all
prognostic risk groups? Strahlenther Onkol 2006;182(3):135-41.
http://www.ncbi.nlm.nih.gov/pubmed/16520907
207. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in
combination with external beam radiotherapy in the radical treatment of prostate cancer:
initial results of a randomised phase three trial. Radiother Oncol 2007;84(2):114-20.
http://www.ncbi.nlm.nih.gov/pubmed/17531335
208. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M. Randomized
trial comparing iridium implant plus external-beam radiation therapy with external-beam
radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin
Oncol 2005;23(6):1192-9. http://www.ncbi.nlm.nih.gov/pubmed/15718316
209. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS. High dose
rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose
rate palladium seeds. Journal of Urology 2004;171(3):1098-104.
http://www.ncbi.nlm.nih.gov/pubmed/14767279
210. Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, Krauss DJ,
Gonzalez J. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy
boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006;66(2):416-23.
http://www.ncbi.nlm.nih.gov/pubmed/16879929
211. Yoshioka Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, Shiomi H, Imai A, Nakamura
S, Shimamoto S, Inoue T. High-dose-rate interstitial brachytherapy as a monotherapy for
localized prostate cancer: treatment description and preliminary results of a phase I/II
clinical trial. Int J Radiat Oncol Biol Phys 2000;48(3):675-81.
http://www.ncbi.nlm.nih.gov/pubmed/11020563
212. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an
adequate staging procedure for prostate cancer? Journal of Urology 2002;168(2):514-8.
http://www.ncbi.nlm.nih.gov/pubmed/12131300
213. Briganti A, Chun FK, Salonia A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F,
Karakiewicz PI. Validation of a nomogram predicting the probability of lymph node invasion
among patients undergoing radical prostatectomy and an extended pelvic
lymphadenectomy. Eur Urol 2006;49(6):1019-26.
http://www.ncbi.nlm.nih.gov/pubmed/16530933
214. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical
prostatectomy for prostate cancer. Urology 2006;68(1):121-5.
http://www.ncbi.nlm.nih.gov/pubmed/16806432
215. Touijer K, Rabbani F, Otero JR, Secin FP, Eastham JA, Scardino PT, Guillonneau B. Standard
versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted
probability of nodal metastasis greater than 1%. J Urol 2007;178(1):120-4.
http://www.ncbi.nlm.nih.gov/pubmed/17499306
216. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R. Incidence of positive pelvic
lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or
=10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progressionfree
survival after radical prostatectomy. BJU Int 2006;97(6):1173-8.
http://www.ncbi.nlm.nih.gov/pubmed/16686707
217. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph
node dissection for prostate cancer: experience with more than 1,000 patients. J Urol
2007;177(3):916-20. http://www.ncbi.nlm.nih.gov/pubmed/17296375
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011